HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
MONDAY, Nov. 2, 2020 (HealthDay News) -- Most individuals with COVID-19 have robust immunoglobulin G (IgG) antibody responses against the viral spike protein, which last for about five months, according to a study published in the Oct. 28 issue of Science.
Ania Wajnberg, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues examined the robustness, functionality, and longevity of antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The researchers found that based on a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, the vast majority of infected individuals with mild-to-moderate COVID-19 experienced robust IgG antibody responses against the viral spike protein. Titers were relatively stable for at least a period of about five months; anti-spike-binding titers correlated significantly with neutralization of authentic SARS-CoV-2.
"Although this cannot provide conclusive evidence that these antibody responses protect from reinfection, we believe it is very likely that they will decrease the odds ratio of reinfection, and may attenuate disease in the case of breakthrough infection," the authors write. "We believe it is imperative to swiftly perform studies to investigate and establish a correlate of protection from infection with SARS-CoV-2. A correlate of protection, combined with a better understanding of antibody kinetics to the spike protein, would inform policy regarding the COVID-19 pandemic and would be beneficial to vaccine development efforts."
Several authors disclosed financial ties to the biopharmaceutical industry; Mount Sinai has licensed serological assays to commercial entities and has filed for patent protection for serological assays.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 25, 2022